Sepsis Diagnostics Market by Technology, Product, Method, Test Type, Pathogen, End-user and Region - Forecast to 2025 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Sepsis Diagnostics Market by Technology (Microbiology, PCR, Microarray, Immunoassay, Biomarkers), Product (Reagents, Assay, Instruments, Software), Method, Test Type (Lab, POC), Pathogen (Bacterial, Fungal), End-user and Region - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global sepsis diagnostics market size is expected to reach USD 700 million by 2025 from USD 429 million in 2019, at a CAGR of 8.5%.

The demand is expected to grow due to the rising incidence of sepsis, a growing number of surgical procedures, high incidence of hospital-acquired infections, and increasing availability of a wide variety of sepsis diagnostic devices. The sepsis diagnostics industry is segmented on the technology, product, method, pathogen, test type, end user, and region.

The blood culture segment accounted for the largest share of the sepsis diagnostics industry, by end-user, in 2019.

Based on end-users, the sepsis diagnostics market is segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. In 2019, blood culture accounted for the largest share of the market due to the increasing incidences of sepsis coupled with the growing adoption of blood culture techniques for the diagnosis of sepsis.

The blood culture media segment accounted for the largest share of the sepsis diagnostics market, by product, in 2019.

The market, by product, is segmented into blood culture media, assays & reagents, instruments, and software. In 2019, the blood culture media segment accounted for the largest share of the sepsis diagnostics industry due to the usage of blood culture testing as the standard diagnostic method for the diagnosis and identification of sepsis across the globe.

North America accounted for the largest share of the sepsis diagnostics market in 2019.

North America accounted for the largest share of the global market in 2019, followed by Europe. This can primarily be attributed to the extensive availability of advanced sepsis diagnostic technologies, well-established distribution channels, and significant public awareness about the clinical benefits of diagnostic products in risk assessment for infectious diseases.

Some of the prominent players in the sepsis diagnostics market are bioMrieux (France), Becton Dickinson Company (US), Danaher (US), Abbott Laboratories (US), Roche Diagnostics (Switzerland), T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia), Response Biomedical (Canada), Axis-Shield Diagnostics (UK), and CytoSorbents (US).

Key Topics Covered

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

4.1 Sepsis Diagnostics: Market Overview

4.2 Sepsis Diagnostics Market, by Technology

4.3 Geographic Analysis: Sepsis Diagnostics Market, by Product and Region

4.4 APAC: Sepsis Diagnostics Market, by Country and End-user

4.5 Sepsis Diagnostics Market, by Pathogen

4.6 Geographic Snapshot of the Sepsis Diagnostics Market

5 Market Overview

5.1 Introduction

5.2 Market Dynamics

5.2.1 Drivers

5.2.1.1 High Incidence of Sepsis

5.2.1.2 Rising Incidence of Hospital-Acquired Infections

5.2.1.3 Growing Funding for Sepsis-Related Research

5.2.2 Restraints

5.2.2.1 Unfavorable Reimbursement Scenario

5.2.2.2 High Cost of Automated Diagnostic Devices

5.2.3 Opportunities

5.2.3.1 Development of Rapid Diagnostic/POC Techniques for Early Sepsis Diagnosis

5.2.3.2 Evolution of Novel Biomarkers for Sepsis Diagnosis

5.2.4 Challenges

5.2.4.1 Lack of Standard Protocols and Awareness

5.2.4.2 Shortage of Skilled Healthcare Professionals

6 Sepsis Diagnostics Market, by Technology

6.1 Introduction

6.2 Blood Culture

6.2.1 Blood Culture Holds the Largest Share of the Technology Market

6.3 Immunoassays

6.3.1 Product Development Efforts by Major Players Have Ensured Demand for Immunoassays

6.4 Molecular Diagnostics

6.4.1 Polymerase Chain Reaction

6.4.1.1 Pcr Holds the Largest Share of the Molecular Diagnostics Market

6.4.2 Microarrays

6.4.2.1 Simultaneous Analysis Capabilities, Accuracy, and Rapidity Have Driven the Use of Microarrays

6.4.3 Peptide Nucleic Acid-Fluorescent in Situ Hybridization

6.4.3.1 PNA-Fish Kits Allow for the Rapid Diagnosis of BSIS

6.4.4 Syndromic Panel-Based Testing

6.4.4.1 High Costs and Accuracy Issues Have Affected Test Adoption

6.5 Flow Cytometry

6.5.1 Lack of Standardized Protocols is a Key Restraint in this Market Segment

6.6 Microfluidics

6.6.1 Growing Adoption of Advanced & Rapid Testing Will Favor Market Growth in this Segment

6.7 Biomarkers

6.7.1 Despite Potential, No Single Ideal Biomarker Has Been Identified for Sepsis Diagnostics

7 Sepsis Diagnostics Market, by Product

7.1 Introduction

7.2 Blood Culture Media

7.2.1 Blood Culture Media Dominate the Products Market

7.3 Assays & Reagents

7.3.1 Increasing Awareness Has Driven the Use of Assays & Reagents

7.4 Instruments

7.4.1 Market is Characterized by a Shift from Traditional & Manual Instruments to Automated Systems

7.5 Software

7.5.1 Rising Use of Automated Instruments Will Ensure Demand for Software

8 Sepsis Diagnostics Market, by Method

8.1 Introduction

8.2 Conventional Diagnostics

8.2.1 Conventional Diagnostics Holds Largest Market Share

8.3 Automated Diagnostics

8.3.1 Automated Diagnostics Segment to Grow at the Highest CAGR

9 Sepsis Diagnostics Market, by Pathogen

9.1 Introduction

9.2 Bacterial Sepsis

9.2.1 Gram-Negative Bacterial Sepsis

9.2.1.1 Gram-Negative Bacteria Cause ~50% of Sepsis Infections

9.2.2 Gram-Positive Bacterial Sepsis

9.2.2.1 Cases of Sepsis Caused by Gram-Positive Bacteria Have Risen in Recent Years

9.3 Fungal Sepsis

9.3.1 Fungemia is the Second-Biggest Cause of Bloodstream Infections

9.4 Other Pathogens

10 Sepsis Diagnostics Market, by Test Type

10.1 Introduction

10.2 Laboratory Tests

10.2.1 Laboratory Tests are the Most Common and Preferred Mode of Testing

10.3 Point-of-Care Tests

10.3.1 Rapidity and Convenience Have Driven Demand for POC Tests

11 Sepsis Diagnostics Market, by End-user

11.1 Introduction

11.2 Hospitals

11.2.1 Hospitals Hold the Largest Share of the Sepsis Diagnostics Market

11.3 Pathology & Reference Laboratories

11.3.1 Independent Laboratories Offer Affordability as Well as the Benefits of Bundled Services

11.4 Research Laboratories & Academic Institutes

11.4.1 Government Support and Rising Awareness Have Ensured Demand for Market Products in this Segment

12 Sepsis Diagnostics Market, by Region

12.1 Introduction

12.2 North America

12.2.1 US

12.2.1.1 US is the Largest Market for Sepsis Diagnostics

12.2.2 Canada

12.2.2.1 Growing Availability of Sepsis Diagnostic Products to Support Market Growth in Canada

12.3 Europe

12.3.1 Germany

12.3.1.1 Germany Accounted for the Largest Share of the European Market

12.3.2 France

12.3.2.1 High Incidence and Rising Awareness Have Supported the Demand for Sepsis Diagnostics in France

12.3.3 UK

12.3.3.1 Government Support and Rising Awareness are Key Drivers in the UK

12.3.4 Italy

12.3.4.1 Sluggish Growth in the Italian Healthcare Sector in the Last Few Years to Restrain the Market Growth

12.3.5 Spain

12.3.5.1 Rising Sepsis Incidence to Drive Market Growth in Spain

12.3.6 Rest of Europe

12.4 Asia-Pacific

12.4.1 Japan

12.4.1.1 Significant Growth in Pneumonia and Infectious Disease Incidence to Support Market Growth in Japan

12.4.2 China

12.4.2.1 Healthcare Infrastructure Improvements to Support Market Growth in China

12.4.3 India

12.4.3.1 Increasing Patient Population and Rising Number of Surgical Procedures are Key Growth Drivers in India

12.4.4 Australia

12.4.4.1 Increasing Number of Sepsis Treatment Procedures Indicates Growth Potential in the Australian Market

12.4.5 South Korea

12.4.5.1 Rising Healthcare Spending Supports Market Growth in South Korea

12.4.6 Rest of Asia-Pacific

12.5 Latin America

12.5.1 Brazil

12.5.1.1 Brazil Accounted for the Largest Share of the Latam Market

12.5.2 Mexico

12.5.2.1 Rising Medical Tourism to Support Market Growth in Mexico

12.5.3 Rest of Latin America

12.6 Middle East & Africa

12.6.1 High Consumption of Immune System-Suppressing Medications is Driving Sepsis Occurrence

13 Competitive Landscape

13.1 Overview

13.2 Market Share Analysis

13.3 Competitive Scenario

13.3.1 Product Launches and Approvals, 2016-2020

13.3.2 Partnerships and Collaborations, 2016-2020

13.3.3 Mergers and Acquisitions, 2016-2020

13.3.4 Market Expansion, 2016-2020

13.4 Competitive Leadership Mapping

13.4.1 Visionary Leaders

13.4.2 Innovators

13.4.3 Dynamic Differentiators

13.4.4 Emerging Companies

14 Company Profiles

14.1 Biomrieux

14.2 Becton, Dickinson and Company

14.3 Danaher

14.4 T2 Biosystems

14.5 Luminex

14.6 Roche Diagnostics

14.7 Thermo Fisher Scientific

14.8 Bruker Corporation

14.9 Abbott

14.10 Immunexpress

14.11 Response Biomedical

14.12 Axis-Shield Diagnostics

14.13 Cytosorbents

14.14 Mitsubishi Chemical Europe

14.15 EKF Diagnostics

14.16 Emerging Players

14.16.1 Seegene

14.16.2 Genmark Diagnostics

14.16.3 Boditech Med

14.16.4 Alpha Laboratories

14.16.5 Alifax S.R.L.

For more information about this report visit https://www.researchandmarkets.com/r/pdt696